EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Tenax Therapeutics's enterprise value is $-2.32 Mil.
Tenax Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-7.68 Mil. Therefore, Tenax Therapeutics's EV-to-EBITDA for today is 0.30.
The historical rank and industry rank for Tenax Therapeutics's EV-to-EBITDA or its related term are showing as below:
TENX'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -7.49 Med: 0.72 Max: 0.92
Current: 0.3
During the past 13 years, the highest EV-to-EBITDA of Tenax Therapeutics was 0.92. The lowest was -7.49. And the median was 0.72.
TENX's EV-to-EBITDA is ranked better than 85.2% of 473
companies
in the Biotechnology industry
Industry Median: 9.22
vs TENX: 0.30
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Tenax Therapeutics EV-to-EBITDA Historical Data
The historical data trend for Tenax Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Tenax Therapeutics's EV-to-EBITDA
For the Biotechnology subindustry, Tenax Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tenax Therapeutics's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tenax Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Tenax Therapeutics's EV-to-EBITDA falls into.
Tenax Therapeutics's current Enterprise Value is $-2.32 Mil.
Tenax Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.68 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Tenax Therapeutics's PE Ratio for today is calculated as:
Tenax Therapeutics's share price for today is $3.60.
Tenax Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-34.240.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Tenax Therapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Tenax Therapeutics (Tenax Therapeutics) Business Description
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TENX has been successfully added to your 